Clinical effectiveness of botulinum toxin (BTX) in the treatment of both neurogenic and idiopathic detrusor overactivity has been demonstrated in several studies. However, different protocols and techniques have been used by authors.
Methods.
Literature review on intradetrusor injection of BTX for detrusor overactivity.
Results.
The greatest clinical experience reports the use of 200 and 300 U Botox®. Available data suggest that clinical efficacy, duration, and the side effect profile is similar at these doses. Very few data, on the other hand, are available regarding the clinical outcomes using the Dysport® preparation; isolated reports support that efficacy is similar when using a dosing range of 500 to 1000 SU with increased risk of systemic side effects using 1000 SU. A variety of injection volumes was used, demonstrating similar efficacy and tolerability profile. Clinical effect duration extends six to ten months in the majority of studies. Data suggest that a repeated injection scheme proves successful in the vast majority of initial responders.
Conclusions.
Safety, effectiveness, specificity and reversibility make BTX a new attractive treatment modality for overactive bladder syndrome. However, more experience is needed to standardize the injection protocol with respect to therapeutic outcomes and adverse effects.
DykstraD.D., SidiA.A., ScottA.B., PagelJ.M., GoldishG.D.. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients.J Urol.1988; 139: 919–22.
2.
KuoH.C.. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity.Urology2003; 61: 550–4.
3.
ZermannD.H., IshigookaM., SchubertJ., SchmidtR.A.. Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgencyfrequency-syndrome refractory to conservative medical treatment and electrical stimulation.Neurourol Urodyn.2001; 20: 412–3, Abstract.
4.
SmithC.P., RadziszewskiP., BorkowskiA., SomogyiG.T., BooneT.B., ChancellorM.B.. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis.Urology2004; 64: 871–5.
5.
KuoH.C.. Prostate botulinum A toxin injection - an alternative treatment for benign prostatic obstruction in poor surgical candidates.Urology2005; 65: 670–4.
6.
BagiP., Biering-SorensenF.. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions.Scand J Urol Nephrol.2004; 38: 495–8.
7.
SchurchB., StohrerM., KramerG., SchmidD.M., GaulG., HauriD.. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.J Urol2000; 164: 692–7.
8.
SchurchB., de SezeM., DenysP.Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.J Urol2005; 174: 196–200.
9.
ReitzA., StohrerM., KramerG.European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.Eur Urol2004; 45: 510–5.
10.
Schulte-BauklohH., MichaelT., SturzebecherB., KnispelH.H.. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder.Eur Urol2003; 44: 139–43.
11.
HajebrahimiS., AltaweelW., CadoretJ., CohenE., CorcosJ.. Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results.Can J Urol2005; 12: 2543–6.
12.
RajkumarG.N., SmallD.R., MustafaA.W., ConnG.. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity.BJU Int2005; 96: 848–52.
13.
RappD.E., LucioniA., KatzE.E., O'ConnorR.C., GerberG.S., BalesG.T.. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience.Urology2004; 63: 1071–5.
14.
KesslerT.M., DanuserH., SchumacherM., StuderU.E., BurkhardF.C.. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?Neurourol Urodyn.2005; 24: 231–6.
15.
PopatR., ApostolidisA., KalsiV., GonzalesG., FowlerC.J., DasguptaP.. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.J Urol2005; 174: 984–9.
16.
SmithC.P., NishiguchiJ., O'LearyM., YoshimuraN., ChancellorM.B.. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.Urology2005; 65: 37–41.
17.
RackleyR.R., FrenklT.L., AbdelmalakJ.B.. Botulinum toxin: the promise of therapy for complex voiding dysfunction.Cont Urol2005; 38–52.
18.
GrosseJ., KramerG., TongT.Q.T., StoherM., JakseG.. Efficacy, dosage, and safety of Dysport English botulinum toxin A in sever neurogenic detrusor overactivity.Eur Urol2005; suppl. 4: Abst 405.
19.
KuoH.C.: Comparison of the therapeutic effects of suburothelial injection of botulinum A toxin at different doses for refractory detrusor overactivity.J Urol2006; 175: 113 (A347).
20.
RuffionA., CapelleO., PaparelP., LericheB., LericheA., GriseP.. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?BJU Int2006; 97: 1030–4.
21.
de PaivaA., MeunierF.A., MolgoJ., AokiK.R., DollyJ.O.. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.Proc Natl Acad Sci U S A.1999; 96: 3200–5.
22.
HaferkampA., KrengelU., ReitzA.Are botulinum-A toxin injections into the detrusor of patients with neurogenic detrusor overactivity safe? Ultrastructural data of detrusor biopsies.Neurourol Urodyn.2003; 22: 499–500.
23.
RappD.E., TurkK.W., BalesG.T., CookS.P.. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder.J Urol2006; 175: 1138–42.
24.
ChuangY.C., YoshimuraN., HuangC.C., ChiangP.H., ChancellorM.B.. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats.J Urol2004; 172: 1529–32.
25.
SampaioF.J.. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract.Int Braz J Urol2003; 29: 176–8.
26.
ApostolidisA., PopatR., YiangouY., CockayneD., FordA.P., DavisJ.B.Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.J Urol2005; 174: 977–82; discussion 982–3.
27.
KheraM., SomogyiG.T., KissS., BooneT.B., SmithC.P.. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury.Neurochem Int2004; 45: 987–93.
28.
ComperatE., ReitzA., DelcourtA., CapronF., DenysP., Chartier-KastlerE.. Histologic Features in the Urinary Bladder Wall Affected from Neurogenic Overactivity-A Comparison of Inflammation, Oedema and Fibrosis With and Without Injection of Botulinum Toxin Type A.Eur Urol2006; 50: 1058–64.
29.
Del PopoloG.. Botulinum-A toxin in the treatment of detrusor hyperreflexia.Neururol Urodyn.2001; 20: 522.
30.
WyndaeleJ.J., Van DrommeS.A.. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor over-activity.Spinal Cord.2002; 40: 599–600.
31.
KuoH.C.. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.Urology2005; 66: 94–8.
32.
SmithC.P., ChancellorM.B.. Emerging role of botulinum toxin in the management of voiding dysfunction.J Urol2004; 171: 2128–37.
33.
KimH.S., HwangJ.H., JeongS.T.Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis.Dev Med Child Neurol2003; 45: 200–6.
34.
MahajanS.T., KentonK., BrubakerL.. Cystoscopic intradetrusor botulinum A toxin injection for the treatment of detrusor over-activity incontinence.J Urol2006; 175: 539, Abst. 1672.
35.
RayF.R., MooreK.H., HansenM.A., BardenJ.A.. Loss of purinergic P2X receptor innervation in human detrusor and subepithelium from adults with sensory urgency.Cell Tissue Res.2003; 314: 351–9.
36.
ChuangY.C., FraserM.O., YuY., ChancellorM.B., de GroatW.C., YoshimuraN.. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor.J Urol2001; 165: 975–9.
37.
SzallasiA., FowlerC.J.. After a decade of intravesical vanilloid therapy: still more questions than answers.Lancet Neurol2002; 1: 167–72.
38.
VemulakondaV.M., SomogyiG.T., KissS., SalasN.A., BooneT.B., SmithC.P.. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation.J Urol2005; 173: 621–4.
39.
LucioniA., RappD.E., GongE.M., FedunokP., BalesG.T.. Botulinum toxin type A injection for overactive bladder: trigone versus trigone-sparing injection.Can J Urol2006; 13; 3291–5.
40.
GrosseJ., KramerG., StohrerM.. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.Eur Urol2005; 47: 653–9.
41.
DoellgastG.J., BrownJ.E., KoufmanJ.A., HathewayC.L.. Sensitive assay for measurement of antibodies to Clostridium botulinum neurotoxins A, B, and E. use of hapten-labeled-antibody elution to isolate specific complexes.J Clin Microbiol.1997; 35: 578–83.
42.
DykstraD.D., PryorJ., GoldishG.. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis. a case report.Arch Phys Med Rehabil.2003; 84: 1399–400.
43.
DykstraD., EnriquezA., ValleyM.. Treatment of overactive bladder with botulinum toxin type B: a pilot study.Int Urogynecol J Pelvic Floor Dysfunct.2003; 14: 424–6.
44.
ReitzA., SchurchB.. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity.J Urol2004; 171: 804; discussion 804–5.
45.
PistolesiD., SelliC., RossiB., StampacchiaG.. Botulinum toxin type B for type A resistant bladder spasticity.J Urol2004; 171: 802–3.
46.
GheiM., MarajB.H., MillerR.Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, doubleblind, placebo controlled, crossover trial.J Urol2005; 174: 1873–7.
47.
DykstraD.D., SidiA.A., ScottA.B., PagelJ.M., GoldishG.D.. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients.J Urol1988; 139: 919–22.
48.
MariaG., DestitoA., LacquanitiS., BentivoglioA.R., BrisindaG., AlbaneseA.. Relief by botulinum toxin of voiding dysfunction due to prostatitis.Lancet1998 Aug 22; 352(9128): 625.
49.
Shulte-BauklohH., MichaelT., SchobertJ., StolzeT., KnispelH.H.. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results.Urology2002; 59: 325–7; discussion 327–8.
50.
ZermannD., IshigookaM., SchubertJ., SchmidtR.A.. Perisphincteric injection of botulinum toxin type A.A treatment option for patients with chronic prostatic pain? Eur Urol2000; 38: 393–9.
51.
MariaG., BrisindaG., CivelloI.M., BentivoglioA.M., SgangaG., AlbaneseA.. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.Urology2003; 62: 259–64; discussion 264–5.
52.
SahaiA., KhanM.S., DasguptaP.. GKT Botulinum Study Group. Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity. Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial.J Urol2007; 177: 2231–6.
